Elevar Therapeutics and Inceptua partner to commercialize Apealea®

By Akshay Kedari  Date: 2020-12-29

Elevar Therapeutics and Inceptua partner to commercialize Apealea®

According to reliable sources, U.S.-based fully integrated biopharmaceutical company, Elevar Therapeutics Inc., has signed an exclusive agreement with Inceptua Group for the commercialization and distribution of its non-cremophor based paclitaxel treatment Apealea® in Europe. 

For the uninitiated, Elevar Therapeutics is a Utah-headquartered organization that focuses on offering medical services to patients who have inadequate or limited therapeutic options. Their patent treatment Apealea® is a water-soluble, intravenously injectable chemotherapy agent that is primarily used to treat ovarian cancer as well as other solid tumors.

Reportedly, the recent collaboration is aimed at leveraging Inceptua’s capabilities in oncology development as well as orphan treatments to strengthen the presence of Apealea® in the European market and optimize the value of its portfolio on a global level.

As per the contract, Inceptua will be granted exclusive rights for the distribution and commercialization of the drug across Europe. However, these rights do not permit the administration in Nordic countries including Iceland, Sweden, Norway, Finland, and Denmark.

Stefan Fraenkel, Chief Executive Officer of Inceptua, was reported saying that the company has observed great potential in Apealea® for treatment of ovarian cancer among patients who have a low tolerance for paclitaxel formulated with cremophor. The organization’s established sales force, vast market access capabilities, and robust distribution networks will bolster the commercialization of the treatment throughout Europe, he added.

It is to be noted that Apealea® was granted marketing authorization by regulatory authorities for its administration in the European Economic Area in November 2018, in combination with carboplatin for treating adult patients diagnosed with platinum-sensitive epithelial ovarian cancer. The treatment has recently been granted Orphan Drug Designation by the U.S. FDA (Food and Drug Administration), as cited by credible sources.

About Inceptua Group

Established in 1997, Inceptua focuses on delivering products and services for clinical trials and providing medication for various patient programs. The company’s primary objectives include offering customer-centric services at all stages of a drug lifecycle, facilitating access to unlicensed medicines, and providing an international commercialization platform for pharmaceutical as well as biopharmaceutical products.  

Source credits –

https://www.prnewswire.com/news-releases/elevar-therapeutics-announces-licensing-agreement-with-inceptua-group-for-commercialization-of-apealea-paclitaxel-micellar-in-europe-301198507.html

About Author

Akshay Kedari     aeresearch.net

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

Square to acquire installment payment firm Afterpay for USD 29 Bn

Square to acquire installment payment firm Afterpay for USD 29 Bn

By Akshay Kedari

With the increasing competition in the buy now pay later (BNPL) arena for U.S. consumers, digital payments firm Square Inc. recently announced its plans of acquiring BNPL company Afterpay Ltd. in an all-stock deal valued at USD 29 billion. The San F...

Hyundai Motor, LG Energy Solution to launch battery plant in Indonesia

Hyundai Motor, LG Energy Solution to launch battery plant in Indonesia

By Akshay Kedari

This new battery production plant will be built in the Karwang Regency. It will reportedly have a yearly output of around 10 gigawatt-hours of batteries. South Korean multinational conglomerates Hyundai Motor Company and LG Energy Solution Ltd. ...

Amazon’s ‘Key for Business’ raises security concerns for U.S apartments

Amazon’s ‘Key for Business’ raises security concerns for U.S apartments

By Akshay Kedari

American technology and e-commerce giant, Amazon.com Inc. has reportedly been using ‘Key for Business’- a system that enables the company’s delivery agents to gain access to apartment complexes without requiring to be buzzed in by r...

Volvo Cars might take full control of its Chinese stake ahead of IPO

Volvo Cars might take full control of its Chinese stake ahead of IPO

By Akshay Kedari

Swedish luxury automobile manufacturer Volvo Cars Corporation reportedly signed an agreement with Zhejiang Geely Holding Group to buy out from their decade-long joint ventures to gain complete ownership of its facilities in China. According to relia...

Lamborghini expects sale volumes to hit record highs in India this year

Lamborghini expects sale volumes to hit record highs in India this year

By Akshay Kedari

Italian luxury sports car manufacturer, Automobili Lamborghini S.p.A. is reportedly expecting substantial growth in sales volumes in India this year as the carmaker is experiencing a V-shaped upturn in demand after the easing out of COVID-19 pandemic...